How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’s WASHINGTON, March 08, 2024 (GLOBE NEWSWIRE) -- The maker of donanemab, Eli Lilly, announced today that the Food and Drug Administration (FDA) will convene an advisory committee to consider the...